A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2019
At a glance
- Drugs ME 401 (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors MEI Pharma
- 07 Feb 2019 According to a MEI Pharma media release, dosing of the first patient in this trial is expected in the first calendar quarter of 2019.
- 14 Dec 2018 Status changed from not yet recruiting to recruiting.
- 06 Dec 2018 Status changed from planning to not yet recruiting.